**Name of Journal:** World Journal of Clinical Pediatrics

**Manuscript NO:** 74890

**Manuscript Type:** ORIGINAL ARTICLE

**Retrospective Study**

*The frequency of celiac disease and distribution of HLA-DQ2/DQ8 haplotypes among siblings of children with celiac disease*

Yasin Sahin, Serdar Mermer, Derya Aydin Sahin

**Abstract**

**BACKGROUND**

Celiac disease (CD) is a multifactorial disease but genetic factors play an major role in its etiology. It has been known that human leucocyte antigen (HLA)-DQ2/8 haplotypes are one of the most important genetic predisposing factors. The risk of developing CD in first-degree relatives and especially siblings of celiac patients is quite high because of having the same HLA haplotypes.

**AIM**

To evaluate the frequency of CD and the distribution of HLA DQ2/8 haplotypes in siblings of celiac patients.

**METHODS**

Patients with biopsy-proven CD and their siblings were included in the study, those who did not have HLA genotyping were excluded from the study. All siblings were on a gluten-containing diet. The HLA genotyping, tissue transglutaminase antibody (tTG) IgA antibody test, and total IgA test were performed in all participants.

**RESULTS**
A total of 57 celiac patients and their 112 siblings and were included in the study. The mean age of celiac patients and siblings were 10.30±3.87 years and 9.90±6.11 years, respectively. HLA-DQ2/8 alleles were detected in 98.2% of patients with CD and 90.2% of siblings of celiac patients. HLA-DQ genotypes were present in all siblings diagnosed with CD. Tissue transglutaminase antibody IgA test was found to be positive in 16 siblings. CD was diagnosed in 12 siblings (10.7%) by intestinal biopsy.

CONCLUSION
The prevalence of CD was found to be 10.7% in siblings of celiac patients in our study. One third of the siblings diagnosed with CD were asymptomatic. We detected HLA-DQ alleles in 98.2% of celiac patients and 100% in siblings diagnosed with CD. In addition, one of the two siblings was diagnosed with CD 1 year later and the other 4 years later. Therefore, we suggest that siblings of celiac patients should be followed up with clinical findings as well as HLA analysis and serological examination. Since the developing risk of CD is much higher in asymptomatic siblings, we recommend that siblings should be screened for CD even if they are asymptomatic.

INTRODUCTION
Celiac disease (CD) is an autoimmune systemic disease triggered by gluten intake in genetically susceptible individuals characterised by various degrees of small intestinal damage (1). It is a multifactorial disease but genetic factors play an major role in its etiology. It has been known that human leucocyte antigen (HLA)-DQ2/8 genotypes are one of the most important genetic predisposing factors (2-4).

The risk of developing CD in first-degree relatives and especially siblings of celiac patients is quite high because of having the same HLA genotypes and the environmental triggers such as gut microbiome (5-8).

It has been reported that the risk of developing CD is higher in siblings of celiac patients compared to other first-degree relatives (9-11).
Celiac disease may be asymptomatic for years or even be diagnosed 10 years after the first symptom appears (12). It has been reported that approximately half of the first-degree relatives of celiac patients newly diagnosed with celiac disease are completely asymptomatic (2,8,13).

Early diagnosis of CD is very important for the prevention of long-term complications of CD such as osteoporosis, growth retardation, infertility and malignancy. Although there are many studies on the frequency of CD in first-degree relatives of celiac patients, the number of studies investigating the frequency of CD and the distribution of HLA DQ2/8 in siblings of celiac patients is rare (8,13-15). The aim of our study was to evaluate the frequency of CD and the distribution of HLA DQ2/8 haplotypes in siblings of celiac patients.

MATERIALS AND METHODS

This study was carried out between February 2017 and June 2020. Patients with biopsy-proven CD and their siblings were included in the study, those who did not have HLA genotyping were excluded from the study. All siblings were on a gluten-containing diet. The current study was approved by the Local Ethics Committee (Toros University, Mersin, Turkey, 17.06.2020/41). The patient who was first diagnosed with CD was defined as an index case.

CD was diagnosed according to the ESPGHAN 2012 guidelines (2). 57 celiac patients and their 112 siblings were included in the study. Three patients who do not have any siblings were not included in the study. The HLA genotyping, tissue transglutaminase antibody (tTG) IgA antibody test, and total IgA test were performed in all participants. tTG IgA antibody levels were measured by enzyme-linked immunosorbent assay method (Diametra, Spello PG, Italy). The cut-off value for tTG IgA was 20 U/mL. Total IgA levels were measured by nephelometric method (Siemens Diagnostics, Marburg, Germany).

Gastroduodenoscopy and small intestinal biopsy were performed in all patients with tTG positivity. Four biopsies from duodenum and at least one biopsy from bulb were
obtained. All intestinal biopsy specimens are evaluated according to modified Marsh-Oberhuber classification (16). Marsh stage 0: normal mucosa, Marsh stage 1: increased intraepithelial lymphocytosis (>40 Lymphocytes per 100 epithelial cells), Marsh stage 2: increased intraepithelial lymphocytosis with crypt hyperplasia, Marsh stage 3a: increased intraepithelial lymphocytosis with crypt hyperplasia and partial villous atrophy, Marsh stage 3b: increased intraepithelial lymphocytosis with crypt hyperplasia and subtotal villous atrophy, and Marsh stage 3c: increased intraepithelial lymphocytosis with crypt hyperplasia and total villous atrophy. If the pathology result was compatible with Marsh stage 2 or stage 3, the patient was diagnosed with CD.

RESULTS
A total of 57 celiac patients and their 112 siblings and were included in the study. Of 112 siblings, 54 (48.20%) were female. 33 (57.89%) of 57 celiac patients were female. The mean age of celiac patients and siblings were 10.30±3.87 years and 9.90±6.11 years, respectively (Table 1).

HLA-DQ2/8 alleles were detected in 98.2% of patients with CD and 90.2% of siblings of celiac patients (Table 2). A total of 57 celiac patients, 57.9% of them had HLA-DQ2, 29.8% had HLA-DQ2/8 and 10.5% had HLA-DQ8. Both alleles were found to be negative in 1.8% of them. HLA-DQ genotypes were present in all siblings diagnosed with CD (Table 3). Tissue transglutaminase antibody IgA test was found to be positive in 16 siblings. CD was diagnosed in 12 siblings by intestinal biopsy (Table 3). The pathology result of 10 siblings was compatible with Marsh stage 3. The prevalence of CD was found to be 10.7% in siblings of celiac patients in our study and this rate was 22.7 times higher than the general population. Gastrodudenoscopy could not be performed in four of 16 siblings because of parental refusal. Out of 100 cases not diagnosed with CD, 59 had HLA-DQ2 positivity, 16 had HLA-DQ2/8 positivity, 14 had DQ8 positivity, and 11 had both negativity of HLA-DQ2 and 8.

Seven of those 12 celiac patients had anemia, six of them had growth retardation, and four of them had no symptoms.
HLA-DQ alleles were also positive in all four patients who refused to undergo gastroduodenoscopy.

No IgA deficiency was detected in both groups.

Two siblings of 3 index cases were diagnosed with CD. The first sibling of the first index case was diagnosed 2 mo later, and the second sibling 1 year later (when looking at the 2nd serology); the first sibling of the second index case was diagnosed with CD 4 years later (in the second serology examined with an interval of 2 years) and the second sibling was diagnosed with CD 4 mo after the first. The two siblings of the other index case were also diagnosed with CD within 3 mo.

**DISCUSSION**

The estimated prevalence of CD is 1% in the world, and this rate varies in different geographical regions (2,17). The reason of that may be due to differences in genetic susceptibility and changes in dietary gluten intake.

With the identification of the major role of HLA-DQ2/8 in genetically susceptible individuals, it has been reported that the negative detection of both HLA-DQ2 and DQ8 in first-degree relatives of celiac patients does not require further investigation for CD (18,19). On the contrary, it has been reported that the risk of CD is higher in individuals having HLA-DQ2 homozygous (19,20).

In the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 2012 guidelines, HLA genotyping is recommended as the initial screening test for CD especially at risk groups such as first-degree relatives of celiac patients (2). It has been shown that HLA-DQ analysis is helpful in predicting CD especially in first-degree relatives of celiac patients (21-23). The absence of HLA-DQ2 and DQ8 most likely excludes CD, but celiac specific antibody tests are required to diagnose CD in the presence of those alleles (21). While some authors have suggested that HLA analysis can be used in the diagnosis of CD, others have suggested that it is a good alternative for determining genetic predisposition (24,25).
The prevalence of CD in siblings of celiac patients is 5.9-18.3% (8,10,13-15,26). As consistent with the literature, the prevalence of CD was found to be 10.7% in siblings of celiac patients in our study. 12 siblings were diagnosed with CD by intestinal biopsy. Four siblings (25%) with positive tTg refused gastroduodenoscopy. In a study, the rate of those who did not accept biopsy (22.2%) was similar to our study (13). The real prevalence of CD could not be estimated, as there were cases who refused the biopsy.

In a systematic review, it has been reported that the prevalence of CD in sisters of celiac patients is approximately two times higher than in brothers (26). Contrary to this, the prevalence of CD was equal in male and female genders in our study. The reason for that may be the study was cross-sectional, 4 cases with positive serology did not accept endoscopy. For this reason, we may not have been able to fully determine the risk of CD. The other reason is that our study have a short follow-up period. Some seronegative individuals may be seropositive in the future and be diagnosed with CD.

In a multicenter study conducted in Europe, it has been reported that 90% of celiac patients have the HLA-DQ2 genotype, and 5 to 10% of them have DQ8 (27). Those genotypes are found in 40-65% of first-degree relatives of celiac patients and 18-30% of the general population (10,11,28). HLA-DQ8 positivity is higher in America, Asia, Chile and Cuba compared to Europe (29-32). In our study, 57.9% of celiac patients had HLA-DQ2, 29.8% had HLA-DQ2/8 and 10.5% had HLA-DQ8. Both alleles were found to be negative in 1.8% of them. HLA-DQ2/8 ratios vary from region to region (27,29-32).

HLA analysis was performed on all siblings of celiac patients in the current study. HLA antigens were positive in 90.2% of siblings of celiac patients. As consistent with our study, HLA antigens were found to be positive in all siblings of celiac patients (100%) in another study conducted in our country (15).

In our study, out of 100 cases not diagnosed with CD, 59 had HLA-DQ2 positivity, 16 had HLA-DQ2/8 positivity, 14 had DQ8 positivity, and 11 had both negativity of HLA-DQ2 and 8. In a study with the same number of cases as our case, 49 of 100 cases whose
siblings of celiac patients were not diagnosed with CD were HLA-DQ2 positivity, 6 had HLA-DQ8 positivity, two of them had HLA-DQ2/8 positivity, and 43 had both negativity of HLA-DQ2 and DQ8 (10). The reason for that is the difference of HLA-DQ2/8 ratios vary from region to region (27,29-32).

In the study by Bonamico et al, it has been shown that the use of HLA genotyping as a first step can be used to exclude one-third of first-degree relatives, but it has been reported that patients with DQ2 and DQ8 negatives can be overlooked (10). Also, it has been suggested that it may be more useful to evaluate the first degree relatives of celiac patients together with tTG antibody test and HLA typing.

HLA antigens are detected in 94.7-100% of siblings of celiac patients diagnosed with CD (10,13,15). In parallel with the literature, HLA antigens were detected in all 12 siblings of celiac patients diagnosed with CD in our study.

It has been known that HLA-DQ alleles have a high prevalence among celiac patients (2,15,21,34). Those alleles may determine susceptibility to CD in risk groups such as first-degree relatives of celiac patients (20). It has been reported that the frequency of HLA-DQ2/8 is high in risk groups such as first-degree relatives of celiac patients (2,35).

We found a high rate of positive HLA-DQ alleles in celiac patients and their siblings in compatible with the literature.

It has been reported that 30.0-78.9% of siblings of celiac patients diagnosed with CD are asymptomatic (8,13-15,35). As consistent with the literature, one third of our patients were found to be asymptomatic. Since patients diagnosed with silent CD have a high prevalence, asymptomatic siblings of celiac patients should be screened for CD.

It has been suggested that HLA genotyping can be used to exclude 25-33% of first-degree relatives from serological follow-up (10,24,36-38). The absence of HLA DQ alleles has a high negative predictive value for CD, positive results indicate only a genetic predisposition (39,40).

Celiac disease can occur at any age, a negative serological test once does not mean that there will be no celiac disease in the future. Many studies have been conducted on serologically negative celiac patients (41-44). In the study by Pittschiel et al, serological
positivity was detected in 3 cases with HLA-DQ2 positivity after more than 10 years of follow-up, and then CD was diagnosed (41). In parallel with that study, CD was diagnosed in one of two cases with HLA-DQ2 positive one year later and the other 4 years later in our study. CD can be seen in any period of life. Since the follow-up period was short in our study, we think that other cases with positive HLA antigens may be diagnosed with CD in the future. Therefore, we think that cases in high-risk group should be followed clinically and serologically.

In a Western cohort, only 0.5% of celiac patients were found to have HLA-DQ negativity (19). In a recent study, it has been reported that HLA-DQ typing is insufficient to identify individuals susceptible to CD and could not be used to diagnose CD (45). In another study conducted in Iran, HLA-DQ negativity was found to be 3.9% (46). HLA-DQ2 and DQ8 were found to be negative in 5% of cases in another study (10). In parallel with that studies, HLA-DQ antigens were found to be negative 1.8% in celiac patients in our study. In that studies, it has been reported that the risk of developing CD is very low in cases with HLA-DQ negativity. It has been suggested that cases with HLA-DQ2/8 negativity should be followed clinically and serologically every 2 or 3 years (10). For this reason, it has been suggested that HLA analysis would be more appropriate in cases where it is difficult to diagnose.

In a study conducted in healthy school children in our country, the prevalence of CD was found to be 0.47% (47). In the current study, the prevalence of CD in siblings of celiac patients was found to be 10.7%. That is, we found that the prevalence was 22.7 times higher than in the general population.

**Limitations of the study:** Fifteen celiac patients and their 28 siblings refused to participate in the study. If they did, the results would have been different and the power of study would have been more. Another limitation is the short follow-up period. CD may develop over time in our serologically negative cases. For these reasons, we think that we could not estimate the real prevalence of CD.
CONCLUSION

In conclusion, the prevalence of CD was found to be 10.7% in siblings of celiac patients in our study and this rate was 22.7 times higher than the general population. One third of the siblings diagnosed with CD were asymptomatic. We detected HLA-DQ alleles in 98.2% of celiac patients and 100% in siblings diagnosed with CD. Thus, CD was shown to be associated with HLA-DQ2 and DQ8 genotypes. In addition, one of the two siblings was diagnosed with CD 1 year later and the other 4 years later. Therefore, we suggest that siblings of celiac patients should be followed up with clinical findings as well as HLA analysis and serological examination. Since the developing risk of CD is much higher in asymptomatic siblings, we recommend that siblings should be screened for CD even if they are asymptomatic.

ARTICLE HIGHLIGHTS

Research background

Celiac disease (CD) is an autoimmune systemic disease triggered by gluten intake in genetically susceptible individuals. It is a multifactorial disease but genetic factors play an major role in its etiology. It has been known that human leucocyte antigen (HLA)-DQ2/8 genotypes are one of the most important genetic predisposing factors. The risk of developing CD in siblings of celiac patients is quite high because of having the same HLA genotypes and the environmental triggers such as gut microbiome.

Research motivation

Although there are many studies on the frequency of CD in first-degree relatives of celiac patients, the number of studies investigating the frequency of CD and the distribution of HLA DQ2/8 in siblings of celiac patients is rare. Because of that we aimed to evaluate the frequency of CD and the distribution of HLA-DQ2/8 haplotypes in siblings of celiac patients.

Research objectives
To investigate the frequency of CD and the distribution of HLA DQ2/8 haplotypes in siblings of celiac patients

Research methods
The current study was carried out between February 2017 and June 2020. Biopsy-proven celiac patients and their siblings were included in the study. CD was diagnosed according to the ESPGHAN 2012 guidelines. 57 celiac patients and their 112 siblings were included in the study. All siblings were on a gluten-containing diet. The HLA genotyping, tissue transglutaminase antibody (tTG) IgA antibody test, and total IgA test were performed in all participants. Gastroduodenoscopy was performed in all patients with tTG positivity. Four biopsies from duodenum and at least one biopsy from bulb were obtained. All intestinal biopsy specimens are evaluated according to modified Marsh-Oberhuber classification.

Research results
HLA-DQ2/8 alleles were detected in 98.2% of patients with CD and 90.2% of siblings of celiac patients. Tissue transglutaminase antibody IgA test was found to be positive in 16 siblings. CD was diagnosed in 12 siblings by intestinal biopsy. Seven of those 12 celiac patients had anemia, six of them had growth retardation, and four of them had no symptoms.

Research conclusions
The prevalence of CD was found to be 10.7% in siblings of celiac patients in our study and this rate was 22.7 times higher than the general population. One third of the siblings diagnosed with CD were asymptomatic. We detected HLA-DQ alleles in 98.2% of celiac patients and 100% in siblings diagnosed with CD. Thus, CD was shown to be associated with HLA-DQ2 and DQ8 genotypes. In addition, one of the two siblings was diagnosed with CD 1 year later and the other 4 years later. Therefore, we suggest that
siblings of celiac patients should be followed up with clinical findings as well as HLA analysis and serological examination. Since the developing risk of CD is much higher in asymptomatic siblings, we recommend that siblings should be screened for CD even if they are asymptomatic.

Research perspectives
According to the current study, we suggest that the siblings of celiac patients should be followed up with clinical findings as well as HLA analysis and serological examination. Since the developing risk of CD is much higher in asymptomatic siblings, we recommend that siblings should be screened for CD even if they are asymptomatic.

ACKNOWLEDGEMENTS
We would like to thank to the pathologists and pediatricians for their help to the study.
<table>
<thead>
<tr>
<th>1</th>
<th>ecronicon.com</th>
<th>120 words — 3%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Sahin Yasin. &quot;Clinical evaluation of children with celiac disease: A single-center experience&quot;, Archives of Clinical Gastroenterology, 2020</td>
<td>40 words — 1%</td>
</tr>
<tr>
<td>3</td>
<td>Margarida Maria Castro-Antunes, Sergio Crovella, Lucas Andre Cavalcanti Brandão, Rafael Lima Guimaraes et al. &quot;Frequency distribution of HLA DQ2 and DQ8 in celiac patients and first-degree relatives in Recife, northeastern Brazil&quot;, Clinics, 2011</td>
<td>26 words — 1%</td>
</tr>
<tr>
<td>4</td>
<td>&quot;ESPGHAN 52nd Annual Meeting Abstracts&quot;, Journal of Pediatric Gastroenterology &amp; Nutrition, 2019</td>
<td>18 words — 1%</td>
</tr>
<tr>
<td>5</td>
<td>brief.land</td>
<td>16 words — &lt; 1%</td>
</tr>
<tr>
<td>6</td>
<td>avesis.cu.edu.tr</td>
<td>12 words — &lt; 1%</td>
</tr>
</tbody>
</table>